The pharma company Genfit has announced supportive data from a study involving a non-invasive algorithm driven blood test for the fatty liver disease known as NASH, a potential replacement
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
